Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei
Authors:
- Tristan D. YanTYTristan D. Yan
- Matthew D. HortonMHMatthew D. Horton
- Gary G. FermanisGFGary G. Fermanis
- David L. MorrisDMDavid L. Morris
- 17 March 2009
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 99 (5) , 292-295
Abstract
Background: Pleural dissemination of pseudomyxoma peritonei (PMP) is considered an advanced/terminal disease. We review our experience with thoracic cytoreductive surgery (CRS) and intraoperative hyperthermic intrathoracic chemotherapy (HITHOC) for the treatment of pleural recurrence of PMP following previous intraabdominal surgery.Patients and Methods: An observational study of five patients with pleural dissemination from PMP treated with thoracic CRS and intraoperative HITHOC with mitomycin C for 90 min at 41.5°C.Results: There were three men. The mean age was 46.5 (10.5) years. Postoperatively, one patient developed Grade I, one patient developed Grade III and one patient developed Grade IV postoperative complication. Two patients had an unremarkable postoperative recovery. Only one patient has died 38 months since treatment from abdominal complication of this disease with no evidence of thoracic disease. The four surviving patients are still alive 4.6–47.4 months after treatment. Two patients have evidence of an intraabdominal recurrence.Conclusions: Thoracic CRS and intraoperative HITHOC is a safe and effective procedure to treat pleural dissemination from PMP. Long‐term disease‐free survival can be achieved from this treatment for which no other potentially curative therapy has been described. J. Surg. Oncol. 2009;99:292–295.Keywords
This publication has 16 references indexed in Scilit:
- Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Annals of Surgical Oncology, 2007
- A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma PeritoneiAnnals of Surgical Oncology, 2006
- Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasmsBritish Journal of Surgery, 2006
- Etiology and prognostic significance of massive pleural effusionsRespiratory Medicine, 2005
- The etiology, clinical presentation, and management of pseudomyxoma peritoneiSurgical Oncology Clinics of North America, 2003
- Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosisCancer, 2001
- Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndromeAnnals of Surgical Oncology, 2000
- A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to “Pseudomyxoma Peritonei”American Journal of Surgical Pathology, 1995
- Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.Journal of Clinical Oncology, 1992
- Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.Journal of Clinical Oncology, 1991